Comparing two brain stimulation sites for Parkinson's disease medication needs

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with Parkinson's disease who had deep brain stimulation surgery at CHRU of Nancy between 2014 and 2024. The surgery targeted the subthalamic nucleus (STN) or the ventral intermediate nucleus (VIM).

Sex

All sexes can join.

Disease stage

Clinical diagnosis of Parkinson's disease.

Earlier treatment

Had deep brain stimulation surgery of the subthalamic nucleus (STN) or ventral intermediate nucleus (VIM) at CHRU of Nancy between 2014 and 2024. Had dopaminergic treatment before surgery.

Main reasons for not taking part

• No clinical diagnosis of Parkinson's disease
• No initial dopaminergic treatment
• Surgery not done at CHRU of Nancy
• Death within 1 year after surgery

The registry criteria, word for word

What the trial wants to find out

This study compares the effects of deep brain stimulation (DBS) of the thalamic VIM nucleus versus the subthalamic nucleus (STN) on the levodopa equivalent daily dose (LEDD) in patients with Parkinson's disease. The goal is to determine whether VIM stimulation, typically used for tremor, can also reduce medication needs. It hypothesizes that STN stimulation leads to greater LEDD reduction, but VIM may offer moderate benefits in selected case

The 2 groups in the trial

• VIM group

  Patients in this group underwent deep brain stimulation (DBS) targeting the ventral intermediate nucleus (VIM) of the thalamus. VIM stimulation is primarily used for the control of tremor in Parkinson's disease patients, particularly those with tremor-dominant symptoms. This group includes individuals who were selected for DBS due to the prominence of tremor in their clinical presentation, with less emphasis on other motor symptoms such as bradykinesia or rigidity

• NST group

  Patients in this group underwent DBS targeting the subthalamic nucleus (STN). STN stimulation is commonly used in patients with advanced Parkinson's disease, particularly for those who experience motor fluctuations, dyskinesias, and who require a significant reduction in dopaminergic medication. This group includes patients who were selected for DBS based on their overall motor symptoms, including bradykinesia and rigidity, with or without tremor predominance